Hartan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hartan

Quick Facts

Property Description
Active ingredient Losartan potassium
Form Oral film-coated tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Management of chronic high blood pressure
Origin / Status Synthetic / Prescription Only (Rx)

What is Hartan and What is its Primary Purpose?

Hartan is a prescription-only medication containing the active ingredient Losartan potassium, which belongs to the Angiotensin II Receptor Blocker (ARB) class of drugs. Its primary therapeutic goal is the long-term management of high blood pressure (hypertension), serving as a therapy for reducing cardiovascular risk.

This class of medicine is used for stabilizing blood pressure to reduce a patient's long-term risk of severe health issues, such as stroke and heart attack. A unique feature of Losartan, which differentiates it from other ARBs, is its uricosuric effect, meaning it may help promote the excretion of uric acid.

Formulation and Core Composition

Hartan is typically provided as a film-coated oral tablet and is derived from a synthetic, non-peptide compound created through complex chemical synthesis. Losartan potassium was the first compound of the ARB class to be granted approval in 1995.

Because of its specific molecular structure, Hartan offers a therapeutic alternative for patients who may experience the persistent, dry cough sometimes associated with the chemically distinct Angiotensin-Converting Enzyme (ACE) inhibitors. This difference in tolerability profile makes Hartan an option for managing blood pressure in a wide range of patients.

What side effects are possible with Hartan?

Possible Side Effects and Safety Information

The official safety profile for Hartan (Losartan potassium) is derived from regulatory analysis of clinical trials and post-marketing data, organizing adverse reactions by both the physiological system affected and their reported frequency. This structure communicates the full scope of officially documented risks.


Frequency-Classified Adverse Reactions

Adverse effects are categorized according to regulatory standards:

  • Common (ge 1/100 to < 1/10): Dizziness, vertigo, upper respiratory infection, nasal congestion, back pain, and asthenia (weakness)/fatigue. Hypotension (low blood pressure) and renal impairment are also common in specific high-risk patient populations.
  • Uncommon (ge 1/1,000 to < 1/100): Headache, sleep disorders, palpitations, angina pectoris, abdominal pain, nausea, vomiting, rash, pruritus (itching), and edema (swelling).
  • Rare (ge 1/10,000 to < 1/1,000): Hypersensitivity reactions, including anaphylaxis, angioedema, vasculitis, and hepatitis.

Adverse reactions are grouped across multiple System-Organ Classes, including the Nervous System (dizziness, headache), Gastrointestinal system (nausea, constipation), Musculoskeletal system (back pain, myalgia), and the Vascular system (hypotension).


Serious Adverse Reactions and Safety Constraints

The most critical events documented in regulatory labeling include Angioedema (swelling of the face, lips, or throat) and the risk of Fetal Toxicity; Losartan is contraindicated for use during the second and third trimesters of pregnancy. There is also a documented risk of Hyperkalemia (high potassium levels) and Acute Renal Failure, particularly in susceptible patients.

Population-Specific Constraints define use limits, notably the contraindication for patients with severe hepatic impairment. Furthermore, symptomatic hypotension may occur especially after the first dose or following a dose increase, a time-related pattern noted in the official regulatory documentation.

Overdose and Emergency Response

Overdose: When to Seek Immediate Medical Help

Official regulatory information for Hartan (valsartan) defines the principal risk of overdose as an exaggeration of its blood pressure-lowering effect.

Overdose with this medication, or products containing valsartan, may lead to pronounced systemic hypotension (extremely low blood pressure), often resulting in symptoms such as dizziness or fainting.

In rare or highly severe instances, particularly with high exposure or co-ingestion, the low blood pressure may progress to shock or be accompanied by a dangerously fast or slow heartbeat.


Summary of Overdose Presentations

System Affected Documented Clinical Manifestation
Cardiovascular Pronounced hypotension (low blood pressure)
Neurological Dizziness, fainting
Severe Risk Factors Shock, potentially fatal outcomes, fast or slow heartbeat

Emergency Response Instruction

If you suspect an overdose of Hartan, you must seek immediate medical attention.

Contact a healthcare professional, the nearest hospital emergency department, or a regional Poison Control Centre without delay, even if the person appears to have no symptoms. Prompt medical evaluation is required to monitor vital signs and manage the excessive decrease in blood pressure, which is the primary danger associated with taking more than the prescribed amount.

Therapeutic Uses of Hartan

Quick Facts About Hartan

  • Therapeutic Domains: Management of elevated blood pressure (hypertension).
  • Additional Use: Support for individuals with diabetic kidney disease and high blood pressure.
  • Cardiovascular Support: Helps reduce the potential for serious complications, including stroke, in certain high-risk patients.

Hartan is a therapeutic intervention indicated for managing a range of conditions related to cardiovascular health. The primary role of this medication is in the management of high blood pressure, a condition that necessitates consistent care to avoid associated long-term health concerns. The treatment is one part of a comprehensive management strategy, which often includes necessary lifestyle modifications.

For individuals with type 2 diabetes who also present with elevated blood pressure, Hartan is utilized to provide support for kidney function. This specialized application helps in the overall management of diabetic nephropathy, a condition that requires careful clinical monitoring.

Furthermore, this therapeutic option may be prescribed to reduce the risk of stroke in patients who have both high blood pressure and left ventricular hypertrophy (enlargement of the heart's main pumping chamber).

This medication is an important component of guideline-directed medical therapy for heart failure with reduced ejection fraction. It works to ease the strain on the heart, contributing to better overall performance and stability for individuals managing this chronic condition.

Eligibility and Restrictions for Use

Who Can and Cannot Use Hartan?

Population eligibility for Hartan (Losartan potassium) is defined by regulatory guidelines, restricting use based on age, physiological status, and specific comorbidities.


Contraindicated Populations (Must Not Use)

Classification Status in Official Labeling
Pregnancy Contraindicated in the 2nd and 3rd trimesters (must be discontinued immediately if detected) [1.3, 1.4].
Organ Function Contraindicated in patients with severe hepatic impairment (severe liver disease) [1.8, 2.4].
Dual Therapy Contraindicated with aliskiren in patients who have diabetes or renal impairment [1.5, 2.4].

Eligibility and Restricted Use

Population Group Regulatory Eligibility Status
Adults (18+ years) Approved for all established indications [2.1].
Pediatric (6–18 years) Approved for hypertension only. Use is not recommended for children under 6 years or those with a GFR < 30 mL/min/1.73 m^2 [1.8, 2.1].
Hepatic Impairment Restricted use: Patients with mild-to-moderate impairment require a lower starting dose [1.9, 2.2].
Volume Depletion Conditional use: Correction of volume depletion (e.g., from high-dose diuretics) is required before starting, or a lower initial dose must be used [1.4, 2.2].
Lactation Not recommended for breastfeeding mothers, especially when nursing a newborn or premature infant [1.1, 1.9].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Hartan (Losartan potassium) is defined by its effects on blood pressure and potassium regulation, as well as its metabolism by liver enzymes.

Documented Interaction Restrictions

Category Officially Documented Restriction
Dual RAS Blockade Co-administration with Aliskiren is contraindicated in patients with diabetes or moderate-to-severe renal impairment. Combining with ACE inhibitors is generally not recommended.
Potassium Levels Co-administration with Potassium-Sparing Diuretics (e.g., spironolactone) and Potassium Supplements is documented to increase the risk of hyperkalemia.
Metabolic Modulation Fluconazole is officially documented to inhibit CYP2C9, which decreases the plasma concentration of the active metabolite, while Rifampicin is documented to reduce it.
Efficacy and Renal Risk Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are documented to reduce Losartan's antihypertensive effect and increase the risk of renal function changes, particularly in the elderly.
Other Agents Losartan is documented to increase serum concentrations of Lithium, potentially raising the risk of toxicity. Co-use with alcohol or other blood pressure-lowering agents may result in additive hypotensive effects.

These interactions outline constraints for co-administration. They necessitate regulatory caution, particularly for combinations that affect kidney function, electrolyte balance, or Losartan's systemic exposure.

Mechanism of Action

Hartan is a small molecule that functions as a selective angiotensin II type 1 receptor (AT1) antagonist. The drug selectively accumulates in vascular smooth muscle, adrenal glands, and kidney tissue, where AT1 receptors are prevalent. AT1 receptors are G-protein-coupled receptors that, upon activation by the endogenous peptide Angiotensin II (Ang II), initiate a signaling cascade.

Hartan non-competitively inhibits the binding of Ang II to the AT1 receptor, thereby preventing receptor activation. This blockade interrupts the intracellular signaling pathway mediated by Gq protein coupling, which normally leads to the activation of phospholipase C and subsequent increases in intracellular calcium. The resulting downstream molecular consequences include a reduction in the vasoconstrictive signal and a decrease in the release of aldosterone from the adrenal cortex. System-level physiological modulation is characterized by vasodilation in arterioles, resulting from the relaxation of vascular smooth muscle, and a reduction in fluid and sodium retention mediated by decreased aldosterone activity. This coordinated physiological response leads to systemic vascular resistance reduction.

Dosage and Administration Information

Hartan (Losartan potassium) is administered exclusively by the oral route as a film-coated tablet. The protocol for use is built upon a once-daily schedule, which should be maintained at approximately the same time each day to ensure treatment consistency. The tablets can be taken with or without food.

Official Dosage and Use Protocol

Administration Scope Detail
Route of Administration Oral administration only.
Frequency Pattern Once daily.
Intake Condition With or without food.
Preparation Tablets should be swallowed whole with water.

Standard Dosing Regimens

The standard starting dose for adults with hypertension is 50 mg once daily. The dose can be adjusted up to a maximum recommended limit of 100 mg once daily. Specific regimens, such as for heart failure, may require a lower initial dose of 12.5 mg once daily, with gradual titration up to a maximum of 150 mg.

Population Adjustments and Procedural Rules

A starting dose of 25 mg once daily is utilized for patients presenting with hepatic impairment or intravascular volume depletion. Pediatric dosing (ages 6–18) is determined by body weight, with a maximum dose of 100 mg. Treatment effect is typically assessed after three to six weeks of initiation or dose change. If a dose is missed, it is recommended against taking a double dose; the regular schedule should be resumed immediately.

Recent Clinical Evidence

Research evidence / Overview of Studies for Hartan

This overview describes the scope of clinical research conducted on Hartan (Losartan potassium), focusing on the types of studies, the populations examined, and the outcomes that were monitored in the scientific literature. It presents a factual summary of the evidence landscape without offering medical advice or making claims about personal health outcomes.


Evidence for Use in Chronic High Blood Pressure Management

The use of Hartan in managing chronic elevated blood pressure (hypertension) has been a primary focus of large-scale clinical research, including extensive Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses. Studies tracked the occurrence of major Cardiovascular Events, such as nonfatal stroke, myocardial infarction, and cardiovascular death, over multi-year periods. Research documented measured changes in blood pressure, and outcomes related to composite cardiovascular events were monitored in the observed populations. Losartan use was associated with measured changes in serum uric acid levels.

What remains uncertain is a direct, head-to-head comparison trial involving every single medication within the Angiotensin II Receptor Blocker (ARB) class. Evidence related to the maintenance of the observed effects over periods longer than five years for all patient types is still emerging from real-world, non-trial settings.


Evidence for Use in Diabetic Kidney Disease

Hartan has been evaluated in specialized, large-scale double-blind, placebo-controlled trials focusing on adults with Type 2 Diabetes, established hypertension, and evidence of proteinuria (excess protein in the urine). The research examined whether treatment was associated with a difference in the time it took for patients to reach a complex, composite endpoint, including the rate of decline of kidney function or the need for dialysis. The primary studies documented a difference in the proportion of patients in the Losartan group versus the placebo group who reached the composite endpoint.

Evidence is limited for patients with Type 1 Diabetes. Furthermore, due to exclusion criteria, there is limited information for long-term outcomes in patients with more advanced stages of kidney failure who were not yet on dialysis.


Evidence for Use in Stroke Risk Reduction in High-Risk Patients

Specific, long-term Randomized Controlled Trials (RCTs) were conducted to explore the medicine's association with reducing the risk of stroke in patients with both essential hypertension and Left Ventricular Hypertrophy (LVH). Findings indicated a difference in the measured rate of stroke events between the Losartan-based regimen and the control regimen in the overall population studied. Results from this research apply only to the specific populations studied, and subgroup findings were mixed in the original research.


Evidence in Special Subgroups and Uncertainties

Research has included large numbers of older adults in major trials, with findings generally describing patterns of outcomes observed in this group. Data for children under the age of six for treating high blood pressure is limited. For patients with mild to moderate liver impairment, studies suggest that outcomes may be affected, and data for individuals with severe hepatic impairment remain very limited.

The overall evidence quality varies across studies, and research provides context but not individual predictions about long-term health.

Frequently Asked Questions (FAQ)

Common questions about Hartan (FAQ)


Q: How quickly does Hartan start to work?

The blood pressure-lowering effect from Hartan is generally observed to be gradual. While the medication is taken once daily for consistency, the full therapeutic effect, according to official documents, is typically assessed after four weeks of starting treatment or following a dose change.


Q: How long do the effects of Hartan last?

The medication is typically taken once daily, which implies the therapeutic effects are designed to cover a 24-hour period. While the active ingredient Losartan has a short half-life, its more potent active compound remains in the body longer, with a terminal half-life of 6 to 9 hours.


Q: Can Hartan be taken with common pain relievers?

Regulatory documents advise caution regarding the co-administration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen. Combining these medicines may reduce the blood pressure-lowering effect of Hartan and potentially increase the risk of changes to kidney function.


Q: Is it okay to take Hartan with vitamins or supplements?

Official labeling specifically warns against taking potassium supplements or salt substitutes that contain potassium. This is due to the potential for the combination to cause hyperkalemia (high potassium levels in the blood), which is a documented risk.


Q: What is the difference between Hartan and other similar medicines?

Hartan contains Losartan, which belongs to the Angiotensin II Receptor Blocker (ARB) class. One documented difference is that ARBs are often used as an alternative to ACE inhibitors for patients who experience a persistent, dry cough. Another finding in studies is Losartan’s potential to promote the excretion of uric acid.


Q: What foods or drinks should be avoided while on Hartan?

Regulatory information notes that salt substitutes often contain potassium, which can increase blood potassium levels. Official information also notes that the concurrent use of alcohol may result in an additive hypotensive effect (drop in blood pressure).


Q: Is Hartan safe for older adults (seniors)?

Clinical studies supporting the use of Hartan included a large number of older adults (those over 65). The data generally described that blood pressure responses were similar to those observed in younger patients.


Q: What are the long-term effects of taking Hartan?

The medication is prescribed for the long-term management of chronic conditions, such as high blood pressure. Studies examined whether treatment was associated with a difference in the measured rate of major cardiovascular events, such as stroke and myocardial infarction, in the populations observed.


Q: What should I do if I notice a change in my heart rate while taking Hartan?

Official guidance states that symptoms such as an irregular or fast heartbeat or feeling light-headed should be reported to a healthcare provider immediately. These symptoms are documented as potential signs of high potassium levels or other serious adverse reactions.


Q: What is the purpose of the black box warning on Hartan, if it has one?

The most serious warning on the product label is regarding Fetal Toxicity. The warning mandates the discontinuation of the drug immediately upon detection of pregnancy in the second or third trimester. This requirement is due to the documented risk of injury or death to the developing fetus.


Q: Can Hartan affect blood sugar levels?

The official side effects profile lists hypoglycemia (low blood sugar) as an uncommon adverse reaction that can occur. Hartan is also studied and indicated for use in specific populations, including those with Type 2 Diabetes and established kidney disease.


Q: Why do official documents caution against Hartan for people with liver conditions?

Official information indicates that patients with liver impairment may require a lower starting dose because liver function affects the drug's metabolism. If the liver is compromised, the body may not clear the medication as effectively, potentially leading to higher exposure to the active compound.


Q: Is the purpose of Hartan to treat symptoms or the underlying cause?

The purpose of Hartan is to help manage chronic high blood pressure. It works by blocking the action of Angiotensin II, a hormone that contributes to high blood pressure, thereby addressing a core physiological mechanism of the condition rather than providing a cure.


Q: Is it safe to drive while taking Hartan?

Official patient information advises caution regarding operating machinery or driving. It notes that the drug may cause dizziness, lightheadedness, or fainting, particularly when treatment is initiated.


Q: Is there a generic version of Hartan?

Yes, the medication containing the active ingredient Losartan potassium is widely available as a generic drug.


Q: Can Hartan make me feel anxious or depressed?

The official product label lists depression as an uncommon adverse reaction. Any changes in mood are documented as adverse events that should be discussed with a healthcare provider.


Q: Is it possible to become dependent on Hartan?

Hartan is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). Therefore, it is not generally associated with potential for abuse or dependence.


Q: Does Hartan interact with grapefruit juice?

While some studies have indicated a mild pharmacokinetic interaction, it is generally not considered clinically significant based on regulatory information. It is noted that consistency in diet is helpful for patients taking this medicine.


Q: Why is Hartan sometimes prescribed for something other than its main use?

The official regulatory label only lists three specific approved uses: high blood pressure, diabetic kidney disease, and reducing stroke risk in certain patients. Any other use is not included in the official documentation.


Q: Are there any specific laboratory tests required when taking Hartan?

The prescribing information indicates that routine monitoring of specific blood values is necessary. This monitoring includes assessments of kidney function (serum creatinine) and electrolyte levels, particularly potassium.


Q: Can Hartan affect weight—either gain or loss?

Weight change itself is not listed as a common side effect. However, the official documentation lists edema (swelling or fluid retention) as an uncommon adverse reaction, which can result in a temporary increase in weight.


Q: Does Hartan contain any common allergens?

Like many tablets, Hartan contains the active drug plus various excipients (inactive ingredients). Official documents note that it may contain ingredients like lactose monohydrate, which is relevant for individuals with specific intolerances.


Q: How is the name 'Hartan' pronounced?

The generic name of the active ingredient, Losartan, is typically pronounced lō-ˈsär-ˌtan.


Q: Is Hartan a controlled substance?

No, the medication is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA).


Q: What kind of specialist usually prescribes Hartan?

Any licensed clinician is permitted to prescribe this medication. However, in complex cases, input from specialists such as cardiologists (heart doctors) or kidney specialists may be recommended.


Q: What should be done if an interaction with another medicine is suspected?

The official patient guidance specifies that if a drug interaction is suspected or if a patient experiences new or worsening side effects, they should seek advice from a doctor or pharmacist immediately.


Q: Has Hartan ever been recalled?

Specific generic products containing Losartan potassium have been subject to recalls globally since 2018. This was due to the presence of trace levels of nitrosamine impurities in some manufacturing batches.


Q: How long does it take for Hartan to leave the system?

Based on the terminal half-life of its active metabolite, Hartan is generally considered to be largely cleared from the body within approximately 33 to 50 hours.

How should Hartan be stored and disposed of?

Storage Requirements

Hartan (losartan potassium) tablets must be stored at Controlled Room Temperature (CRT), which is officially defined as 20 C to 25 C (68 F to 77 F). The regulatory labeling permits brief temperature excursions between 15 C and 30 C.

To maintain the product's stability, the medication must be stored in its original container, kept tightly closed, and protected from excessive heat, light, and moisture. It is a mandatory safety instruction to keep Hartan out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Hartan must adhere to official regulatory guidance. Losartan potassium is not classified as a medicine that should be flushed down the toilet. If a medication take-back program is unavailable, unused tablets should be removed from the container, mixed with an undesirable substance (such as used coffee grounds), and sealed in a bag before being placed in the household trash. Identifying information should be removed from the original container before discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hartan found in:

A-Z Index: